52 results about "Animal Sources" patented technology

The invention belongs to the field of bioactive protein peptide materials, and provides an animal-derived composite fermented skin-tendering protein peptide and a preparation method thereof. According to the invention, bovine-derived collagen and fish-derived protein are subjected to synergistic fermentation to prepare a protein peptide core, and the outer surface of the protein peptide core is coated with an edible gelatin and chondroitin sulfate composite layer; the excellent performance that a small molecule peptide core with the molecular weight being 500-1500 Da, a stable coating layer with the coating rate being 80-99%, the glycine-proline-hydroxyproline sequence collagen peptide fragment accounting for 30-60% and the pH responsive swelling ratio being 1.5-3.0 are achieved, the technical problems that traditional protein peptide is poor in stability and low in bioavailability are solved, and the protein peptide has wide application value in the field of skin care products.

The invention belongs to the technical field of microbiological detection, and particularly relates to a primer and a method for detecting salmonella and a drug-resistant gene thereof and application of the primer and the method. The gene of the salmonella is invA, and the drug resistance genes are blaCTX-M, blaNDM-1, blaTEM-1 and blaOXA; the gene of the salmonella is invA, and the drug resistance genes of the salmonella are blaCTX-M, blaNDM-1, blaTEM-1 and blaOXA; the primers comprise inner primers and outer primers of invA, blaCTX-M, blaNDM-1, blaTEM-1 and blaOXA, a primer group is designed according to conserved regions of a salmonella invA gene and part of beta-lactam drug-resistant genes blaNDM-1, blaTEM-1, blaOXA and blaCTX-M, a detection method of SYBR-LAMP and HNB-LAMP technologies is established, and screening of part of beta-lactam drug-resistant genes carried by animal-derived pathogenic strains is realized.

The invention provides a high-protein feed raw material and a preparation method thereof, and belongs to the field of protein feeds.The preparation method comprises the steps that animal-derived organs are selected, an animal-derived organ enzyme solution is obtained through a pretreatment means, and natural protein components in the animal-derived organ enzyme solution are reserved to serve as crude protein nutritional ingredients; step 2, adding a substrate and a methyl donor into the animal-derived visceral organ enzyme liquid, and generating guanidinoacetic acid and creatine through an enzymatic synthesis reaction to obtain a mixed liquid; and step 3, carrying out enzyme system inactivation, centrifugal filtration, drying and crushing on the mixed solution to obtain a finished product. According to the invention, guanidinoacetic acid and creatine are synthesized by in-situ catalysis of animal-derived visceral organ natural enzyme systems, and can be naturally fused with protein components, so that the problem of compatibility is avoided, and growth functional factors do not need to be added from an external source; natural enzyme systems of animal livers and kidneys are directly utilized, industrial enzymes do not need to be purchased, and the natural enzyme systems are more adaptive to a raw material system; protein, natural enzyme systems and mineral substances in the raw materials are synchronously utilized, so that one material has multiple purposes.

The application discloses a freeze-drying protective agent for Streptococcus pneumoniae without animal source, and belongs to the field of microorganism preservation. The freeze-drying protective agent is composed of the following components: 1-5% (weight / volume) soybean peptone, 1-5% (weight / volume) trehalose, 4-8% (weight / volume) mannitol and 0.3-1.5% (volume / volume) glycerol, and the rest is water. The freeze-drying protective agent can better maintain the activity of Streptococcus pneumoniae, and the effect is equivalent to that of a skimmed milk protective agent or a commercially available freeze-drying protective agent without animal source, but the freeze-drying protective agent does not contain animal source components and has low cost.

A pharmaceutical composition comprising: an active pharmaceutical ingredient (API); 1-45 wt% non-gelatin matrix former comprising hydroxypropyl methylcellulose (hypromellose, HPMC), methyl cellulose,

The present invention provides a textured plant protein defined as a fibrous plant protein material having a protein content of at least 40 wt.% relative to dry matter wherein the textured plant protein is prepared by extruding a feed composition at a moisture content of 18.1-25.9 wt.%, the feed composition comprises: a) a source of plant protein from seeds, cereals, algae, fruits, leaves or legumes, comprising at least 65 wt.% of plant protein relative to dry matter; and b) a source of tuber protein comprising at least 75 wt.% of tuber protein relative to dry matter, and c) a filler, In addition, the invention provides food products comprising the TVP of the invention, as well as methods for obtaining these products, and the use of TVP in food products to replace meat of animal origin.

The present invention relates to an ACCS gene, a protein and the use thereof. An involved ACCS protein mutant is formed by means of mutating a proline residue at position 134 and a tryptophan residue at position 136 of an animal-derived wild-type ACCS protein into a glutamine residue and a tyrosine residue, respectively. The involved ACCS protein mutant can be used in the intervention and treatment of a variety of diseases comprising brain diseases, and provides a new regimen and approach for the intervention and treatment of brain diseases.

The invention relates to the technical field of hydrogel, in particular to diseased animal source amino acid nutritional hydrogel for smart agriculture and a preparation method thereof.The diseased animal source amino acid serves as a nutritional ingredient, and the diseased animal source amino acid is stably integrated into a hydrogel network through photo-initiation through modification treatment; the preparation method comprises the following steps: by taking multi-aldehyde hemp cellulose as a carrier, grafting with compound amino acid through Schiff base reaction to obtain grafted compound amino acid; then taking the grafted compound amino acid as a core material and starch octenylsuccinate as a wall material to prepare a compound amino acid microcapsule; one of polyvinyl alcohol, polyethylene glycol, polyacrylamide and polyvinylpyrrolidone is used as an additive to be compounded with a conventional fertilizer; arabic gum, carboxymethyl chitosan and sodium alginate are compounded to serve as a degradable hydrogel matrix, acrylic acid is grafted to a polymer network, compound amino acid microcapsules with double bonds on the surfaces serve as nutritional ingredients, and the hydrogel is prepared through light-induced polymerization.

The invention provides a fermentation flavoring agent for dogs and a preparation method thereof, and the preparation method comprises the following steps: (1) raw material pretreatment: animal source treatment: taking 40-50 parts of dog preferred animal source raw materials, beating, coating animal fat ointment, and then mincing; carrying out plant source treatment: taking 15-25 parts of plant source raw materials, and carrying out superfine grinding to 60-120 meshes; (2) directional enzymolysis: carrying out enzymolysis on the animal-derived raw material and compound enzyme for 1.5-3 hours under the conditions that the temperature is 40-55 DEG C and the pH value is 5.8-6.8, wherein the compound enzyme consists of flavourzyme, papain and neutral protease according to the ratio of 1: (1.5-2.5): (0.3-0.7); and (3) three-stage stepped fermentation. The prepared fermented flavor agent for dogs has high palatability, strong digestion aiding ability, excellent intestinal protection effect and good storage stability, and is suitable for the requirements of dogs and industrial application.

The invention discloses a preparation method of Brassica rapa L.-derived extracellular vesicle-like particles and an application of the Brassica rapa L.-derived extracellular vesicle-like particles in pulmonary fibrosis resistance. The preparation method comprises the following steps: raw material pretreatment and homogenate preparation: cleaning and grinding the common turnip, adding the common turnip into PBS (Phosphate Buffer Solution) which is 1.5 times of the mass of the medicinal material, soaking for 180 minutes, putting into a homogenizer to prepare homogenate, filtering, standing, and taking supernatant; performing super-gradient centrifugal purification: performing gradient centrifugation, taking supernatant and discarding precipitate; carrying out ultra-high-speed centrifugal collection, namely carrying out ultra-high-speed centrifugal collection on the supernatant at 120000g for 120 minutes and taking precipitate; and re-suspending and storing: re-rotating and precipitating by using PBS to obtain BREVLPs, and storing at ultralow temperature for later use. The extracellular vesicle-like particles (BREVLPs) are prepared from the common turnip for the first time, the preparation method is simple in process, convenient to operate, wide in source of the raw material common turnip, low in cost and suitable for large-scale production, and the problems that existing animal-derived extracellular vesicle-like particles are high in culture cost and complex in process are solved.

The present invention relates to a cell culture medium comprising a hydrolysate composition. In particular, the hydrolysate composition is a plant protein hydrolysate, prepared from soy or wheat enzymatically hydrolysed with alcalase, flavourzyme, neutrase, or protamex. The cell culture medium is suited for culturing animal-derived cells in cultivated meat production, where it offers a cost-effective and sustainable alternative to conventional formulations, facilitating broader commercial adoption. Also disclosed is a method of preparing the cell culture medium.

The present invention relates to a vegan and reusable leather type material of vegetable origin, at least 50% and preferably at least 80% biobased. This material is based on a composition which comprises persimmon (Diospyros kaki) mass and a polymer derived from a polyol of vegetable origin. The invention also discloses the process for obtaining the material. The leather-type material may be used in a variety of goods products in the textile such as clothes, footwear products or accessories. The material has proven to keep the same mechanical properties as the animal origin or synthetic leather, being a sustainable alternative which, in addition, contributes to circular economy. The sustainable material, leather-type of vegetable origin, provides an alternative to known leathers, with less environmental impact.

The invention provides fish-algae paste as well as a preparation method and application thereof, and relates to the field of feed additives. The preparation method of the fish-algae paste comprises the following steps of anchovy pretreatment, algae pretreatment and enzymatic reaction. According to the fish-algae paste as well as the preparation method and the application thereof, animal source components and algae source components are effectively combined, so that adverse effects on effective components in the preparation process can be effectively avoided, and the food calling performance and the health-care gain performance of the fish-algae paste are synchronously improved.

The present invention belongs to the field of biotechnology, in particular the field of biochemical composition and process of preparation thereof. The present invention more particularly relates to composition of ingredients as a serum alternative from an animal origin free source for fetal bovine serum and development of serum alternative from the same. More particularly, the present invention further relates to the specific composition as a serum alternative and application thereof in animal cell culture, biopharmaceutical ingredients in antibody and vaccine preparation, formulation of final drug components and other translation research work like stem cell research.

The present disclosure is directed to a coated paper. The coated paper includes a cellulose layer and at least two coatings on one side of the paper. The first coating applied to the paper is a barrier coating that can be made from a plant or animal derived component, which is preferably water-soluble or water-dispersible, and more preferably water-soluble. The second coating, on the other hand, can be a heat-sealable coating. The coated paper is particularly well suited to constructing packages.

This invention relates to the field of stem cell culture technology, and more particularly to compositions and their applications in stem cell culture. The invention utilizes a composition formed by combining acetate, a pyruvate dehydrogenase kinase (PDK) specific inhibitor, and an HMG-CoA reductase inhibitor to enhance the ability of mesenchymal stem cells to maintain stemness and prevent differentiation during passage. Based on this composition, further incorporating various nutrients, the resulting composition provides ample nutrition to mesenchymal stem cells, maintaining their good proliferative capacity and stemness during passage, even in the absence of serum and animal-derived components, with batch-to-batch stability.

The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol / glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

The invention discloses a stable animal-derived collagen solution for pricking needle injection as well as a preparation method and application of the stable animal-derived collagen solution. The preparation method comprises the following steps: enzymolysis, microfiltration and concentration, dilution and filtration, centrifugal separation, directional fixation and liquid preparation, homogenization and secondary fixation, and mixing and defoaming. By optimizing the preparation method of the collagen solution, the fiber state of the collagen is improved, so that the collagen fibers are uniformly dispersed in the system, the solution is uniform and fine in texture and good in flowability, and can be injected through a small needle head, so that the use requirements on the preparation performance in the beauty fields of hydro-optical needles and the like are met.

The present application relates to the technical field of medicine, in particular to a paeonia lactiflora extracellular vesicle nano-preparation for treating inflammatory diseases, which active ingredient is an extracellular vesicle extracted from paeonia lactiflora tissues.The paeonia lactiflora extracellular vesicle nano-preparation for treating inflammatory diseases, the present application uses paeonia lactiflora, a traditional medicinal plant, as the source of extracellular vesicles, successfully prepares a nano-preparation with clear activity, compared with the vesicles from animal or human cells which are currently studied more, the plant source vesicles completely avoid the risk of animal source pathogen transmission and potential immune rejection.

Provided herein are compositions that are edible and suitable for use in food products, comprising recombinant crosslinked alpha casein, including for example, recombinant crosslinked alpha-s1-casein. Controlling and tailoring crosslinking approach leads to tailoring and improvement of particular product properties and quality attributes of the composition. For example, in dairy-like edible compositions containing only alpha-s1-casein as a dairy protein source, crosslinked recombinant alpha-s1-casein, in comparison with the same non-crosslinked recombinant alpha-s1-casein, enables a more desirable and higher quality product attribute, closer to animal-derived product attributes. Crosslinking has been found to surprisingly improve key analogue cheese properties, including stretch, melt onset, bite resistance, chewiness, and firmness. Surprisingly, crosslinking also enables the reduction of the amount of casein required to achieve desirable levels of key cheese properties.

Provided herein are edible compositions comprising; i. a non-animal derived globular protein, wherein the non-animal derived globular protein is at least partially denatured; and ii. at least one functionalised plant protein; as well as processes for the preparation thereof.

The present disclosure is directed to pharmaceutical compositions using non-animal-based matrix formers and method of making such pharmaceutical compositions. The pharmaceutical compositions can include an active pharmaceutical ingredient, a non-gelatin matrix former, and a structure former. Such a composition can offer comparable and / or improved characteristics compared to other gelatin pharmaceutical compositions.

The invention discloses a preparation method and application of recombinant pepsin, and belongs to the technical field of enzyme engineering. The invention mainly aims to provide a method for commercially preparing recombinant pepsin and application of the recombinant pepsin, so that animal-derived pepsin is replaced by the recombinant pepsin to solve the current application problem. Specifically, the method comprises the following steps: introducing a pepsinogen coding gene containing a signal peptide as shown in SEQ ID NO.2 into pichia pastoris host bacteria to obtain recombinant pichia pastoris; performing high-density fermentation on the recombinant pichia pastoris to obtain fermentation liquor containing recombinant pepsinogen; performing ultrafiltration concentration and filter washing dialysis on the fermentation liquor to obtain a zymogen solution, and activating the zymogen solution under an acidic condition to obtain an active recombinant pepsin solution; and purifying the recombinant pepsin solution to obtain the recombinant pepsin. The zymogen produced by the method disclosed by the invention is high in yield, and the pepsin obtained from the zymogen has the same function as the extracted pepsin.

The invention discloses an animal-source-free culture medium as well as application and a method of the animal-source-free culture medium in production of plague bacillus F1 antigens, and belongs to the technical field of culture mediums. The technical problem to be solved is that a special culture medium which is clear in component, free of animal sources and capable of efficiently and stably promoting plague bacillus growth and F1 antigen expression is lacked in the prior art. According to the key point of the technical scheme, the culture medium composition is provided, and the culture medium composition comprises 25-35 g / L of plant source peptone, 1.25-3.75 g / L of xylose, 5-7 g / L of yeast powder, 1.5-2.5 g / L of glycine, 1.5-4.5 g / L of sodium chloride and 0.5-1.5 g / L of disodium hydrogen phosphate. The culture medium composition does not contain animal source components, is clear in components, and has obvious effects in the aspects of culturing plague bacillus and fermenting to produce F1 antigen.

Provided is a capsule containing a fat and oil containing diacylglycerol, the diacylglycerol containing an omega 3 unsaturated fatty acid, the capsule suppressing coloring of the fat and oil. The capsule is filled with the fat and oil in a capsule coating film of a base agent of a non-animal-derived component, the fat and oil containing 15% by mass or more of diacylglycerol, and 20% by mass or more of the constituent fatty acid of the diacylglycerol being an omega 3 unsaturated fatty acid.

Described are ready-to-use injectable compositions comprising polymeric microspheres or microparticles of non-animal origin, a hydrogel comprising water and a cellulose-derivative gelling agent, and polysorbate 80. Further described are methods of using the ready-to-use injectable compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.

A beverage composition may include a polysaccharide decomposition product, vegetable oil / fat, and an alkali metal element. The content of the polysaccharide decomposition product may be 1.0 wt. % or more. The beverage composition may contain 0.005-0.2 parts by weight of an alkali metal element with respect to 1 part by weight of the polysaccharide decomposition product; 0.0008 parts by weight to 0.030 parts by weight, inclusive, of magnesium with respect to 1 part by weight of the polysaccharide decomposition product; and does not contain any animal-derived raw material or contains some at no more than 0.5 wt. % or less.

The invention discloses a 25-hydroxyvitamin D3 intermediate and a preparation method thereof. The preparation method comprises the following steps: S1, converting a compound (I) into a compound (II); s2, converting the compound (II) into a compound (III); according to the present invention, the phytosterol or the degradation product thereof is adopted as the raw material, such that the source is wide, the price is low, and the method is suitable for industrial scale preparation, is safe compared with the animal source cholesterol, the cholic acid and other raw materials, and has advantages in vaccine and nucleic acid delivery systems.